 VYNE Therapeutics Inc NASDAQ: VYNE announced positive efficacy results from the Phase 1b segment of Phase 1b2a trial of FMX114 in mild-to-moderate atopic dermatitis AD. Mean Atopic Dermatitis Severity Index ADSI scores for FMX114 and vehicle-treated lesions were 7.8 and 8.0,. 